Clinical trial
Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method
NCT07895459 is registered in ClinicalTrials.gov with Masaryk Memorial Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method
- Lead sponsor
- Masaryk Memorial Cancer Institute
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- February 7, 2023
- Completion date
- September 30, 2027
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer (diagnosis), colorectal neoplasms, minimal residual disease
Arms
As registered; 1 arm.
-
CRC Patient Cohort
Patients with colorectal cancer (stages II-IV) receiving standard care and undergoing routine blood draws for ctDNA/MRD monitoring.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
ctDNA Detection Rate for Minimal Residual Disease Assessment
Percentage of patients with detectable circulating tumor DNA (ctDNA) in blood plasma (KRAS G12/G13 mutations assessed by ddPCR) to evaluate minimal residual disease (MRD) after primary therapy.
Lead sponsor's other trials
Masaryk Memorial Cancer Institute, most recent start first.
+9 more trials See the organization page
Similar trials
Same condition (Neoplasm, Residual) and phase, most recent start first.
+30 more trials See the condition page